COMMUNIQUÉS West-GlobeNewswire

Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
20/07/2026
Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year SYDNEY, July 20, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that [...]
CurePSP Awards Record Pathway and Pipeline Grants to Advance PSP and CBD Research
20/07/2026
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CurePSP has announced its largest grant cycle to date, awarding a record number of Pathway and Pipeline Grants to researchers across North America and Europe. The grants [...]
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
20/07/2026
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non- [...]
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
20/07/2026
- Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated - ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood [...]
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
20/07/2026
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using [...]
Applied Biologics Announces Submission of XWRAP® Translational Research Abstract for Consideration at SAWC Fall 2026
20/07/2026
SCOTTSDALE, Ariz., July 20, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced [...]
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
20/07/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to include positive update [...]
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
20/07/2026
New headquarters reflects Collegium's long-term vision and commitment to Massachusetts STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical [...]
TOMI Environmental and Carbonium Core Positioned To Play Key Role in The Onshoring of Essential Strategic Materials for Defense and Global Disinfection
20/07/2026
FREDERICK, Md., July 20, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) (“TOMI”), the leader in decontamination equipment and services with its patented SteraMist ionized Hydrogen Peroxide ( [...]
Novo Nordisk A/S - share repurchase programme
20/07/2026
Bagsværd, Denmark, 20 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
20/07/2026
President & CEO, Sabrina Martucci Johnson, to host interactive investor webcasts featuring corporate updates, commercial strategy and live Q&A SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( [...]
BrainsWay Announces Strategic Investment in Radial Health, Inc.
20/07/2026
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, July 20, 2026 ( [...]
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
20/07/2026
WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
20/07/2026
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
20/07/2026
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track [...]
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
20/07/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new [...]
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
20/07/2026
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study [...]
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
20/07/2026
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients, SB11 provided functional and anatomical [...]
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
20/07/2026
● As of July 18, 2026, net asset value (NAV 1 ) per share was $66.16 ● As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion 2 . Nes-Ziona, Israel, July 20, 2026 ( [...]

Pages